Johnson & Johnson's stock offers value with promising MedTech growth, raised guidance, strong dividends, and bullish ...

We recently published 10 Stocks Jim Cramer Discussed As He Shared Key Insights From Morgan Stanley’s CEO. Johnson & Johnson ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

CNBC’s Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its quarterly report.

The big appeal of Johnson & Johnson over the years has been that it's a relatively safe stock to own, and it also offers an attractive dividend yield of 2.8% -- the S&P 500 average is just over 1.5%.

Johnson & Johnson announced Friday it will split itself into two publicly traded companies, separating its lucrative pharmaceutical and medical devices divisions from the consumer products ...

This 12% rise for JNJ stock since late 2019 can primarily be attributed to 1.Johnson & Johnson’s revenue growth of 16% to $95 billion over the last twelve months, compared to $82 billion in 2019 ...

Johnson & Johnson plans to spin off its consumer health division that sells Listerine and Baby Powder to focus on pharmaceuticals and medical devices in the biggest shake-up in the U.S. company's ...

Johnson & Johnson’s Covid-19 single-shot vaccine was shown to be 66% effective in preventing moderate and severe disease in a global Phase 3 trial, but 85% effective against severe disease, the ...

Johnson & Johnson spun off liabilities — including roughly 38,000 lawsuits — linked to claims of asbestos contamination in its baby powder to a new firm, which then declared bankruptcy.

Johnson & Johnson (JNJ 0.44%) is an iconic global healthcare company. It was originally formed in 1866 when three brothers (Robert, Edward, and James Johnson) founded the company to focus on ...